Ann: Race Board and Management Team Changes, page-391

Like so many of you when the new strategy first released, I am confused , shareprice in decline consistently and then DCB and JC were gone "Fast and Furious".
What does it mean with sudden departure of Damien (New CEO) and The Legendary Mr Robot JC and specially our ex CSO DrT is coming back as a Consultant for RAC.

From my perspective I only focused on the Facts, I do not care about the above internal politics or Egocentric people...etc.

The Facts are:New strategy (DCB) has many flaws and uncertainty (money):

- Firstly AML, this is the reason why I invested in RAC, however I have particularly concerned with this strategy, we only have more than 20 millions dollars left and they planned to spend it all on AML. Historically even after Bisantrene was approved in France 1990, I read that one of many reasons Bisantrene was dropped out of commercial developments at that time was due to the lack of commercial substance (Rare disease and small population of patients). WHAT IF this happened again even we succeeded clinically ? is It too risky to spend all we have on something that may not viable. Since 1990 until today so much already happening in this crowded space (AML) with all the treatments that have been approved recently (please DYOR) and with 900 or more AML clinical trials currently I am afraid that our trial would just become one of them , recruitment proplems and cost blow out is possible.
I am afraid that even AML is proving in clinic successfully again by RAC, it may not bring home the Jucy bacon that we are hoping for.

- Secondly mBC trial (Cardio-protection Blockbuster trial). This area is easy to understand and great potential for a Blockbuster return (Triangle Report). As many of very knowledgeable posters have pointed out that this trials is too costly and timely too long (2028). Small population of patients/ spreading too thin to many sites. And biggest concern is, it may cost from 30-40 millions dollars, where does the money come from ? What If the data that it generated it is not strong enough to attract BP and hoping for partnership (non-dilutive funding) is not good enough.

- Thirdly FTO opportunity:
No real activities at all.This is terrible, we talk alot about Bisantrene being BIC and FIC (FTO inhibitor) and they have no plans to get this into clinic is unacceptable to me.I remembered even EMD AML trial design (by previous BOD) has cleverly incorporated Bisantrene mono agent tail (Stratum two) to obtain FTO Clinical Data. They (new BOD with DrT as a Consultant) may be able to do this again with minimal budget.

Having DrT back as a Consultant giving me hope that we can turn this ship around, He already indicated that he may be able to obtain clinical proof of concept in both Cardio-protection (mBC trial) and FTO inhibitor within the budget that we have.I am so looking forward to his Alternative Strategy. Can't wait.

GLTA and DYOR.